Orbis Medicines

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery using its nGen platform, which systematically designs and tests macrocyclic compounds called nCycles optimized for oral bioavailability and membrane permeability. The company's pipeline targets diseases historically treated with injectable biologics, aiming to provide accessible oral alternatives. Orbis combines high-throughput synthesis, proprietary DNA-encoded libraries of nearly 100 billion compounds, and deep learning to accelerate macrocycle medicine.